The automatic implantable defibrillator: Local ventricular bipolar sensing to detect ventricular tachycardia and fibrillation

Winkle, Roger A.; Bach, Stanley M.; Echt, Debra S.; Swerdlow, Charles D.; Imran, Mir; Mason, Jay W.; Oyer, Philip E.; Stinson, Edward B.

doi:10.1016/0002-9149(83)90120-0

Cited by 85 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a new VT form with a different rate can emerge; therefore, the cut-off rate of the AICD should be programmable. 5. The termination mode of the pacemaker must be adjustable to the changing electrophysiologic conditions so that information about activation will be available.…”

Section: Discussionmentioning

confidence: 99%

Combination of Antitachycardia Pacemaker and Automatic Implantable Cardioverter/Defibrillator for Ventricular Tachycardia

Manz

Gerckens

Funke

et al. 1986

Pacing Clinical Electrophis

View full text Add to dashboard Cite

Antitachycardia pacing for ventricular tachycardia (VT) is associated with the possibility of fibrillating the heart; on the other hand, the frequency of VT and patient discomfort can limit treatment with the automatic implantable cardioverter/defibrillator (AICD). To contribute to the further development of a universal pacemaker, we evaluated the combined use of the antitachycardia pacemaker ("tachylog") and the AICD in five patients with recurrent VT. In the automatic mode, the "tachylog" worked as a bipolar VVI pacemaker. For antitachycardia pacing, a burst of rapid ventricular pacing was delivered at about 80% of the cycle length. During a follow-up period of 5 +/- 2 months (range, 3 to 8) two to 291 successful interventions of antitachycardia pacing were counted from diagnostic data which had been collected by the pulse generator during the course of treatment. When the antitachycardia pacemaker failed to terminate VT, the AICD was activated. In the individual case, between 0 and 41 discharges of the AICD were delivered. The high pulse energy of the AICD did not damage the antitachycardia pacemaker; no interference of the two devices was observed. Future antitachycardia systems should be more flexible with regard to detection and termination modes, combining antitachycardia pacing with back-up defibrillation.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of Antitachycardia Pacemaker and Automatic Implantable Cardioverter/Defibrillator for Ventricular Tachycardia

Manz

Gerckens

Funke

et al. 1986

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

“…This has made treatment of various tachyarrhthmias an empirical trial often inadequate in preventing life threatening arrhythmias. This has necessitated the introduction of many anti-arrhythmia devices which include traditional pacing systems such as inhibited single and dual chamber pacemakers (AA1, VVl, DVl, and DDD) for the control of bradyarrhythmia and for overdrive suppression of certain tachyarrhythmia [9], radio-frequency ablation, and burst pacing systems and implantable cardioverters for control of both su-praventicular tachycardia and fibrillation [10,11], and synthesis of wide spectrum of drugs with varying electrophysiologic properties [12]. Many of these agents had been used for other ailments before serendipity, coupled with some good sense, necessitated their use as antiarrhythmic drugs.…”

Section: Introductionmentioning

confidence: 99%

Interventional role of piperazine citrate in barium chloride induced ventricular arrhythmias in anaesthetized rats

Ghasi¹,

Mbah²,

Pu³

et al. 2009

Biomed Res

View full text Add to dashboard Cite

Interventional potential of piperazine in Barium Chloride (BC) -induced ventricular arrhythmias was investigated in the rats. Various forms of arrhythmias were induced in 10 rats and piperazine (30mg/kg) was given in each case to reverse arrhythmia to sinus rhythm. Five out of six cases of induced ventricular tachycardia (83.3%) were reverted to sinus rhythm by piperazine. Again, 33% success was seen when ventricular fibrillation was induced. One of the three cases was reverted to the sinus rhythm as was also the only case of pulsus bigeminus observed. Piperazine, therefore, has the potential of a good anti-arrhythmic agent. Piperazine was shown to be a more effective antiarrhythmic agent than propranolol against BCinduced ventricular fibrillation. Propranolol not only failed to revert any of the ventricular fibrillations to sinus rhythm, but in two of four cases was not able to reverse the induced ventricular tachycardia. Although piperazine failed to control ventricular fibrillation with the same degree of effectiveness, piperazine has a remarkable therapeutic value in the management of ventricular tachycardia.

show abstract

“…Because the great majority of sudden cardiac death survivors suffers from hemodynamically unstable ventricular tachycardias rather than from ventricular fibrillation, which is observed only at a later stage, if at all, the diagnostictherapeutic spectrum of the device was recently extended to the entire range of ventricular tachyarrhythmias. [5][6][7] This new version of the device (FIGURE 1 ) , now in clinical use, detects and treats both ventricular fibrillation and ventricular tachycardias. The new design includes the addition of a bipolar right ventricular electrode that serves for reliable heart-rate counting, R-wave synchronization and, eventually, for pacing as well.…”

mentioning

confidence: 99%

Clinical Experience With the Implantable Cardioverter‐defibrillator

Mirowski

Reid

Mower

et al. 1984

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The automatic implantable defibrillator: Local ventricular bipolar sensing to detect ventricular tachycardia and fibrillation

Cited by 85 publications

References 5 publications

Combination of Antitachycardia Pacemaker and Automatic Implantable Cardioverter/Defibrillator for Ventricular Tachycardia

Combination of Antitachycardia Pacemaker and Automatic Implantable Cardioverter/Defibrillator for Ventricular Tachycardia

Interventional role of piperazine citrate in barium chloride induced ventricular arrhythmias in anaesthetized rats

Clinical Experience With the Implantable Cardioverter‐defibrillator

Contact Info

Product

Resources

About